Seeking Alpha

As Gilead (GILD +0.6%) awaits FDA approval of its Quad on August 27, Deutsche says U.S. HIV...

As Gilead (GILD +0.6%) awaits FDA approval of its Quad on August 27, Deutsche says U.S. HIV treatment guidelines are already adding the drug. The firm thinks consensus expectations are undervaluing its potential, and its launch will surprise to the upside. The firm raises its price target to $68 from $65 and reiterates its Buy rating on the stock.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|